PubRank

Debomoy K Lahiri

Author PubWeight™ 118.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 2009 2.15
2 An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002 2.00
3 Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 2008 1.92
4 Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci U S A 2005 1.61
5 Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron 2008 1.59
6 Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J 2004 1.56
7 Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med 2009 1.56
8 The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 2005 1.46
9 Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 2002 1.46
10 Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003 1.45
11 A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002 1.43
12 GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010 1.36
13 Early-emerging cognitive vulnerability to depression and the serotonin transporter promoter region polymorphism. J Affect Disord 2007 1.30
14 An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2005 1.25
15 Exposure to lead and the developmental origin of oxidative DNA damage in the aging brain. FASEB J 2006 1.22
16 MicroRNA-101 downregulates Alzheimer's amyloid-β precursor protein levels in human cell cultures and is differentially expressed. Biochem Biophys Res Commun 2010 1.21
17 N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res 2012 1.20
18 High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J Child Neurol 2006 1.18
19 A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res 2006 1.18
20 Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem 2003 1.17
21 Oxidative insults to neurons and synapse are prevented by aged garlic extract and S-allyl-L-cysteine treatment in the neuronal culture and APP-Tg mouse model. J Neurochem 2011 1.15
22 Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: implications for Alzheimer's disease. J Alzheimers Dis 2011 1.14
23 Age-related changes in murine CNS mRNA gene expression are modulated by dietary melatonin. J Pineal Res 2004 1.13
24 Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation 2012 1.13
25 Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 2009 1.10
26 Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res 2010 1.08
27 Apoptotic and behavioral sequelae of mild brain trauma in mice. J Neurosci Res 2007 1.07
28 Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 2011 1.06
29 Targets for AD treatment: conflicting messages from γ-secretase inhibitors. J Neurochem 2011 1.05
30 Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr 2002 1.05
31 Functional characterization of the 5' flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression. FASEB J 2004 1.05
32 Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J Biol Chem 2004 1.04
33 New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 2004 1.03
34 MicroRNA-153 physiologically inhibits expression of amyloid-β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem 2012 1.03
35 Lead (Pb) exposure and its effect on APP proteolysis and Abeta aggregation. FASEB J 2005 1.03
36 Alcohol drinking and deprivation alter basal extracellular glutamate concentrations and clearance in the mesolimbic system of alcohol-preferring (P) rats. Addict Biol 2012 1.02
37 Increased secreted amyloid precursor protein-α (sAPPα) in severe autism: proposal of a specific, anabolic pathway and putative biomarker. PLoS One 2011 1.01
38 Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim Biophys Acta 2008 1.01
39 The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. J Alzheimers Dis 2010 1.00
40 Aluminum and copper in drinking water enhance inflammatory or oxidative events specifically in the brain. J Neuroimmunol 2006 0.99
41 Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. Biochem Soc Trans 2008 0.99
42 Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders. Exp Neurol 2012 0.99
43 Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr Alzheimer Res 2015 0.98
44 Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One 2012 0.98
45 Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. J Med Chem 2003 0.98
46 A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem 2009 0.98
47 The perils of Alzheimer's drug development. Curr Alzheimer Res 2009 0.98
48 Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cells. Neurosci Lett 2009 0.97
49 Temperamental fearfulness in childhood and the serotonin transporter promoter region polymorphism: a multimethod association study. Psychiatr Genet 2007 0.97
50 Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 2004 0.95
51 Functional microRNAs in Alzheimer's disease and cancer: differential regulation of common mechanisms and pathways. Front Genet 2013 0.94
52 The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J Neural Transm (Vienna) 2011 0.94
53 MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J Biol Chem 2013 0.93
54 Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives. J Med Chem 2002 0.93
55 The Alzheimer's amyloid β-peptide (Aβ) binds a specific DNA Aβ-interacting domain (AβID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: characterizing a new regulatory motif. Gene 2011 0.93
56 APH1, PEN2, and Nicastrin increase Abeta levels and gamma-secretase activity. Biochem Biophys Res Commun 2003 0.92
57 Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. Acta Neurobiol Exp (Wars) 2004 0.92
58 Co-localization of the amyloid precursor protein and Notch intracellular domains in nuclear transcription factories. Neurobiol Aging 2008 0.92
59 Molecular and immunocytochemical characterization of primary neuronal cultures from adult rat brain: Differential expression of neuronal and glial protein markers. J Neurosci Methods 2009 0.92
60 Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury. Ann N Y Acad Sci 2004 0.92
61 Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) 2013 0.92
62 Functional characterization of three single-nucleotide polymorphisms present in the human APOE promoter sequence: Differential effects in neuronal cells and on DNA-protein interactions. Am J Med Genet B Neuropsychiatr Genet 2010 0.91
63 Presence of a "CAGA box" in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease. FASEB J 2004 0.91
64 Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease. PLoS One 2013 0.91
65 Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. J Med Chem 2005 0.91
66 Lifespan profiles of Alzheimer's disease-associated genes and products in monkeys and mice. J Alzheimers Dis 2009 0.89
67 Functional activity of the novel Alzheimer's amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. Gene 2011 0.88
68 Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem 2006 0.88
69 The vaccinia virus N1L protein influences cytokine secretion in vitro after infection. Ann N Y Acad Sci 2005 0.88
70 The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region. Ann N Y Acad Sci 2004 0.88
71 Determination of high-affinity choline uptake (HACU) and choline acetyltransferase (ChAT) activity in the same population of cultured cells. Brain Res 2009 0.87
72 Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets 2004 0.87
73 Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau. J Psychiatr Res 2010 0.86
74 Neuroprotection from complement-mediated inflammatory damage. Ann N Y Acad Sci 2004 0.86
75 Neuronal differentiation is accompanied by increased levels of SNAP-25 protein in fetal rat primary cortical neurons: implications in neuronal plasticity and Alzheimer's disease. Ann N Y Acad Sci 2006 0.86
76 Editorial: advances in Alzheimer therapy: something old, something new, something borrowed, something blue. Curr Alzheimer Res 2005 0.85
77 Advances in Alzheimer therapy: development of innovative new strategies. Curr Alzheimer Res 2007 0.85
78 Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. J Pharmacol Exp Ther 2006 0.84
79 Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer's disease and multiple sclerosis. Expert Opin Ther Targets 2015 0.84
80 Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region. J Mol Neurosci 2002 0.84
81 NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells. Brain Res Mol Brain Res 2005 0.84
82 Applying epigenetics to Alzheimer's disease via the latent early-life associated regulation (LEARn) model. Curr Alzheimer Res 2012 0.83
83 'Current Alzheimer Research': update on lipids, estrogen, neurotrophins and their roles in neurodegeneration. Curr Alzheimer Res 2008 0.83
84 Development and validation of the high-quality 'rapid method for swab' to genotype the HTTLPR serotonin transporter (SLC6A4) promoter polymorphism. Psychiatr Genet 2009 0.83
85 Mechanism of promoter activity of the beta-amyloid precursor protein gene in different cell lines: identification of a specific 30 bp fragment in the proximal promoter region. J Neurochem 2004 0.83
86 Novel drug targets based on metallobiology of Alzheimer's disease. Expert Opin Ther Targets 2010 0.83
87 Co-localization and distribution of cerebral APP and SP1 and its relationship to amyloidogenesis. J Alzheimers Dis 2008 0.83
88 Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm. Curr Alzheimer Res 2012 0.83
89 Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease. J Neurochem 2007 0.83
90 Amyloid-β precursor protein synthesis inhibitors for Alzheimer's disease treatment. Ann Neurol 2014 0.82
91 Nicotine lowers the secretion of the Alzheimer's amyloid beta-protein precursor that contains amyloid beta-peptide in rat. J Alzheimers Dis 2002 0.82
92 High-affinity choline uptake (HACU) and choline acetyltransferase (ChAT) activity in neuronal cultures for mechanistic and drug discovery studies. Curr Protoc Neurosci 2012 0.80
93 Prions: a piece of the puzzle? Science 2012 0.80
94 Characterization of the human beta-secretase 2 (BACE2) 5'-flanking region: identification of a 268-bp region as the basal BACE2 promoter. J Mol Neurosci 2006 0.79
95 A single copy of carbonic anhydrase 2 restores wild-type circadian period to carbonic anhydrase II-deficient mice. Behav Genet 2006 0.79
96 An analog of thyrotropin-releasing hormone (TRH) is neuroprotective against glutamate-induced toxicity in fetal rat hippocampal neurons in vitro. Brain Res 2006 0.79
97 Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. J Clin Immunol 2014 0.79
98 Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway. Curr Alzheimer Res 2014 0.79
99 Progress of "Current Alzheimer Research" and future direction. Curr Alzheimer Res 2013 0.79
100 Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholinergic action. Antiinflamm Antiallergy Agents Med Chem 2013 0.78
101 Neurine, an acetylcholine autolysis product, elevates secreted amyloid-beta protein precursor and amyloid-beta peptide levels, and lowers neuronal cell viability in culture: a role in Alzheimer's disease? J Alzheimers Dis 2006 0.78
102 Potential for Stem Cells Therapy in Alzheimer's Disease: Do Neurotrophic Factors Play Critical Role? Curr Alzheimer Res 2017 0.78
103 An integrated approach to genome studies. Science 2011 0.78
104 Editorial--"Current aging science": an important platform for reporting advances in aging-related research. Curr Aging Sci 2010 0.77
105 Chromatographic separation of reaction products from the choline acetyltransferase and carnitine acetyltransferase assay: differential ChAT and CrAT activity in brain extracts from Alzheimer's disease versus controls. J Neurochem 2012 0.77
106 Advances in Alzheimer therapy: understanding pharmacological approaches to the disease. Curr Alzheimer Res 2009 0.77
107 Intravenous immunoglobulin treatment preserves and protects primary rat hippocampal neurons and primary human brain cultures against oxidative insults. Curr Alzheimer Res 2014 0.77
108 Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem 2010 0.76
109 Human primary mixed brain cultures: preparation, differentiation, characterization and application to neuroscience research. Mol Brain 2014 0.76
110 Neuropathological and immunochemical studies of brain parenchyma in acetylcholinesterase knockout mice: implications in Alzheimer's disease. J Alzheimers Dis 2007 0.76
111 K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice. Curr Alzheimer Res 2014 0.76
112 Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease. Curr Alzheimer Res 2013 0.76
113 Design, synthesis and biological assessment of novel N-substituted 3-(phthalimidin-2-yl)-2,6-dioxopiperidines and 3-substituted 2,6-dioxopiperidines for TNF-α inhibitory activity. Bioorg Med Chem 2011 0.76
114 Dietary modulation of age-related changes in cerebral pro-oxidant status. Neurochem Int 2002 0.76
115 Structural and functional characterization of H2 haplotype MAPT promoter: unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for Alzheimer's disease. Gene 2012 0.76
116 Celebrating the fifth year anniversary of current Alzheimer research. Curr Alzheimer Res 2009 0.75
117 Application of a multidisciplinary approach to Alzheimer's disease to develop novel drug targets by integrating biomarkers, imaging, genetic and molecular strategies. Curr Alzheimer Res 2011 0.75
118 Discourse among referees and editors would help. Nature 2006 0.75
119 Melatonin alters age-related changes in transcription factors and kinase activation. Neurochem Res 2010 0.75
120 A SMART plan for new investigators. Science 2009 0.75
121 Advances of Alzheimer's disease research: crossroad of basic and translational studies. Curr Alzheimer Res 2005 0.75
122 Advances in the four major pillars of Alzheimer's disease research: pathobiology, genetics, diagnosis, and treatment. Curr Alzheimer Res 2004 0.75
123 'Current Alzheimer research' helps accelerate the progress of the field. Curr Alzheimer Res 2010 0.75
124 Oral Administration of Thioflavin T Prevents Beta Amyloid Plaque Formation in Double Transgenic AD Mice. Curr Alzheimer Res 2015 0.75
125 A new journal with an integrated approach in the study of aging and longevity. Curr Aging Sci 2008 0.75
126 Perspective on mild cognitive impairment (MCI). Curr Alzheimer Res 2009 0.75
127 Potential intervention by vaccinia virus complement control protein of the signals contributing to the progression of central nervous system injury to Alzheimer's disease. Ann N Y Acad Sci 2002 0.75
128 Progress and vision for 'Current Aging Science'. Curr Aging Sci 2009 0.75